Cargando…
Length of stay, mortality, and readmissions among Medicare cancer patients treated with glucarpidase and conventional care: a retrospective study
PURPOSE: Glucarpidase (Voraxaze) is used to treat methotrexate (Mtx) toxicity in patients with delayed Mtx clearance due to impaired renal function. We examine hospital length of stay (LOS), mortality, and readmission rates for Medicare cancer patients with delayed clearance of Mtx treated with gluc...
Autores principales: | Demiralp, Berna, Koenig, Lane, Kala, Jaya, Feng, Chaoling, Hamlett, Elizabeth G, Steele-Adjognon, Marie, Ward, Suzanne |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6370073/ https://www.ncbi.nlm.nih.gov/pubmed/30799942 http://dx.doi.org/10.2147/CEOR.S188786 |
Ejemplares similares
-
Glucarpidase for Treating Adults with Delayed Methotrexate Elimination Due to Impaired Renal Function: An Economic Simulation Analysis
por: Kala, Jaya, et al.
Publicado: (2023) -
Time spent in prior hospital stay and outcomes for ventilator patients in long-term acute care hospitals
por: Demiralp, Berna, et al.
Publicado: (2021) -
Medicare's hospital readmissions reduction program and the rise in observation stays
por: Wright, Brad, et al.
Publicado: (2023) -
Newborn Length of Stay and Risk of Readmission
por: Harron, Katie, et al.
Publicado: (2017) -
Impact of Length of Stay on Readmission in Hospitalized Patients
por: Rachoin, Jean-Sebastien, et al.
Publicado: (2020)